Beigene Ltd (NASDAQ:BGNE)‘s stock had its “buy” rating reissued by analysts at Maxim Group in a report issued on Wednesday. They presently have a $41.00 price target on the stock. Maxim Group’s price objective would indicate a potential upside of 32.34% from the company’s current price.

The analysts wrote, “BeiGene’s BTK inhibitor (BGB-3111) is going pivotal. We view 3111 as a de- risked, high-value asset in the rich BTK world of therapeutic kinases. Recall that Imbruvica (AbbVie) is indicated for multiple hematological malignancies. The compound was acquired through the $21B acquisition of Pharmacyclics. AstraZeneca recently acquired 55% ownership of Acerta, driven by interest in its BTK inhibitor, for $4B.””

BGNE has been the topic of several other reports. Zacks Investment Research cut Beigene from a “hold” rating to a “sell” rating in a research note on Monday, August 15th. Cowen and Company reiterated a “buy” rating on shares of Beigene in a research note on Monday, June 6th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $40.00.

Analyst Recommendations for Beigene (NASDAQ:BGNE)

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Beigene (NASDAQ:BGNE) remained flat at $30.98 during midday trading on Wednesday. 62,927 shares of the stock were exchanged. The firm’s market cap is $1.02 billion. Beigene has a 52 week low of $22.51 and a 52 week high of $35.60. The stock’s 50-day moving average is $29.30 and its 200-day moving average is $28.99.

Beigene (NASDAQ:BGNE) last issued its quarterly earnings data on Wednesday, August 10th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.68) by $0.05. The business earned $0.40 million during the quarter, compared to analyst estimates of $2.08 million. The company’s revenue was down 71.4% compared to the same quarter last year. On average, equities analysts predict that Beigene will post ($3.45) EPS for the current year.

Large investors have recently made changes to their positions in the company. BlackRock Institutional Trust Company N.A. purchased a new stake in shares of Beigene during the first quarter valued at $112,000. Landscape Capital Management L.L.C. bought a new position in Beigene during the first quarter worth $202,000. Goldman Sachs Group Inc. bought a new position in Beigene during the first quarter worth $807,000. VHCP Management II LLC bought a new position in Beigene during the first quarter worth $3,488,000. Finally, Temasek Holdings Private Ltd bought a new position in Beigene during the first quarter worth $11,138,000.

Beigene Company Profile

BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas.

5 Day Chart for NASDAQ:BGNE

Receive News & Ratings for Beigene Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene Ltd and related companies with's FREE daily email newsletter.